{"id":"W3033907870","doi":"10.1186/s13045-020-00900-7","title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","year":2020,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Genentech; H. Lundbeck A/S; Juno Therapeutics; Incyte; F. Hoffmann-La Roche; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; Servier; TG Therapeutics; Amgen","keywords":"Obinutuzumab; Rituximab; Medicine; Internal medicine; Hematology; Diffuse large B-cell lymphoma; Oncology; CHOP; Lymphoma; Vincristine; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003786596,0.001715821,0.003464801,0.0005232777,0.0005209745,0.001468009,0.001160757,0.001583594,0.004447417],"category_scores_gemma":[0.002529877,0.0008560814,0.002432709,0.0005415303,0.001865361,0.001194162,0.0006936881,0.003035537,0.0007085246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001103433,"about_ca_system_score_gemma":0.002162175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009685003,"about_ca_topic_score_gemma":0.003356116,"domain_scores_codex":[0.9982889,0.001088825,0.00007352809,0.0002190482,0.0001094028,0.000220227],"domain_scores_gemma":[0.9982371,0.0004675188,0.0003708447,0.0001575949,0.000131352,0.0006355285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983497,0.006332619,0.001021456,0.0002095457,0.0009247185,0.00002478054,0.00005173124,0.0002353753,0.001466562,0.00005502383,0.0002476879,0.005933582],"study_design_scores_gemma":[0.9446724,0.05247308,0.001721009,0.00001416514,0.0003369515,0.00001790768,0.00001781031,0.0001920898,0.0001304154,0.000068962,0.0003467898,0.000008387274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884439,0.00235772,0.0006788015,0.0004560101,0.0002988419,0.005752686,0.0007736141,0.0000579406,0.001180565],"genre_scores_gemma":[0.9883831,0.001457113,0.001326368,0.0008718935,0.000284203,0.005023316,0.001002307,0.00002063836,0.001631001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004447417,"threshold_uncertainty_score":0.02002567,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03923046234378376,"score_gpt":0.345590446810616,"score_spread":0.3063599844668322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}